
Starton Holdings, Inc.
STAFiledStarton Holdings, Inc. · Nasdaq Capital Market · Research source · S-1/A · 2026-07-13 · Latest filing · S-1/A · 2026-10-28 SEC ↗
IPO research
Starton Holdings has filed Amendment No. 5 to an S-1 registration statement for a proposed Nasdaq IPO of 5,000,000 common shares under STA.
Full source-backed summary
Starton Holdings is a clinical-stage oncology biotechnology company proposing a 5.0 million-share IPO at an estimated $5.00–$7.00 per share. The filing presents substantial development, financing, going-concern, control and dilution risks; the registration statement remains preliminary and is not yet effective.
Starton Holdings has filed Amendment No. 5 to an S-1 registration statement for a proposed Nasdaq IPO of 5,000,000 common shares under STA.
- Business and development direction
Starton Holdings, Inc.
Current business Future development
Key risks
Risk 1
The company is clinical-stage, has no approved commercial products and has incurred net losses since inception.
Risk 2
The company states that substantial additional capital will be needed even if the offering succeeds.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Source-linked structured inputs are not yet available. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio | Shares |
|---|---|---|---|---|
| 1 | Dominari Securities LLC | |||
| 2 | Revere Securities LLC |
IPO CAPITAL QUALITY
Basis and evidence
S-1/A · 2026-07-13
Starton Holdings has filed Amendment No. 5 to an S-1 registration statement for a proposed Nasdaq IPO of 5,000,000 common shares under STA.
Offering structure
Source and calculation
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Post-offer common stock — base/no option | 37,723,596 | — | |
| Pre-offer common stock — as disclosed | 32,723,596 | — | |
| Pre-offer Common stock — as disclosed | 32,362,606 | — |
Basis and evidence ↗
Prospectus share summary; Shares of Common Stock outstanding after the offering; 37,723,596 shares of common stock (or approximately 38,473,596 if the underwriters’ over-allotment option to purchase additional shares of common stock from us is exercised in full).; selected security: common stock; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Exact input · Post-offer common stock — base/no option: 37,723,596
Prospectus share summary; Shares of Common Stock outstanding before the offering; 32,723,596 shares of common stock as of the date hereof, including shares of common stock issuable in the future, if at all, upon the exchange of an equal number of Exchangeable Shares of Exchangeco (as such terms are defined below).; selected security: common stock; selected scenario: as disclosed; separately stated forfeiture or conversion is not applied to this printed pre-offer count; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock outstanding prior to this offering as of March 31, 2026; identical printed pre-offer counts across columns 4,8; 32,362,606 32,362,606; selected security: Common stock; selected scenario: as disclosed; separately stated forfeiture or conversion is not applied to this printed pre-offer count; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Source inputs required
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Source ↗Source and calculation ↗
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-07-13
Relationship filters
Select for details · Starton Holdings, Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Fotios PlakogiannisBeneficial shares | 3,362,399 | — | — | Shares Beneficially Owned |
| Litsa PerperidisBeneficial shares | 2,924,786 | — | — | Shares Beneficially Owned |
| James KruegerBeneficial shares | 3,174,000 | — | — | Shares Beneficially Owned |
| Kiriakos PerperidisBeneficial shares | 2,014,820 | — | — | Shares Beneficially Owned |
| Pedro Lichtinger WaismanBeneficial shares | 5,982,905 | — | — | Shares Beneficially Owned |
| Eric BaumBeneficial shares | 480,965 | — | — | Shares Beneficially Owned |
| Nitin KaushalBeneficial shares | 463,470 | — | — | Shares Beneficially Owned |
| Roy F. WaldronBeneficial shares | 375,162 | — | — | Shares Beneficially Owned |
| Moses DodoBeneficial shares | 166,200 | — | — | Shares Beneficially Owned |
| Scott L. KahnBeneficial shares | 224,682 | — | — | Shares Beneficially Owned |
| James C. OliverBeneficial shares | 737,050 | — | — | Shares Beneficially Owned |
| All current Executive Officers and Directors as a group (7 persons)Beneficial shares | 8,430,434 | — | — | Shares Beneficially Owned |
| Fotios PlakogiannisBeneficial ownership | — | 10.22%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Fotios PlakogiannisBeneficial ownership | — | 8.7%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Litsa PerperidisBeneficial ownership | — | 8.94%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Litsa PerperidisBeneficial ownership | — | 7.6%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| James KruegerBeneficial ownership | — | 9.7%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| James KruegerBeneficial ownership | — | 8.25%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Kiriakos PerperidisBeneficial ownership | — | 6.06%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Kiriakos PerperidisBeneficial ownership | — | 5.17%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Pedro Lichtinger WaismanBeneficial ownership | — | 17.55%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Pedro Lichtinger WaismanBeneficial ownership | — | 15.02%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Eric BaumBeneficial ownership | — | 1.46%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Eric BaumBeneficial ownership | — | 1.24%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Nitin KaushalBeneficial ownership | — | 1.4%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Nitin KaushalBeneficial ownership | — | 1.2%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Roy F. WaldronBeneficial ownership | — | 1.13%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Roy F. WaldronBeneficial ownership | — | 1%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| James C. OliverBeneficial ownership | — | 2.2%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| James C. OliverBeneficial ownership | — | 1.88%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| All current Executive Officers and Directors as a group (7 persons)Beneficial ownership | — | 23.71%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| All current Executive Officers and Directors as a group (7 persons)Beneficial ownership | — | 20.34%Beneficial | — | Percentage of Shares Beneficially Owned; After Offering |
| Kiriakos PerperidisOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding shares of common stock; not an additive ownership partition |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: The following summary gives effect to the Reorganization in November 2025 and our December 9, 2025 1-for-3 reverse stock split.; complete original context retained; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained |
Source and calculation ↗
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Fotios Plakogiannis(1)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Litsa Perperidis(2)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: James Krueger(3)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Kiriakos Perperidis(4)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Pedro Lichtinger Waisman(5)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Eric Baum(6)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Nitin Kaushal(7)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Roy F. Waldron(8)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Moses Dodo(9)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: Scott L. Kahn(10)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: James C. Oliver(11)
Exact source ownership column: Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Shares Beneficially Owned; source holder: All current Executive Officers and Directors as a group (7 persons)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Fotios Plakogiannis(1)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Fotios Plakogiannis(1)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Litsa Perperidis(2)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Litsa Perperidis(2)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: James Krueger(3)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: James Krueger(3)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Kiriakos Perperidis(4)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Kiriakos Perperidis(4)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Pedro Lichtinger Waisman(5)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Pedro Lichtinger Waisman(5)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Eric Baum(6)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Eric Baum(6)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Nitin Kaushal(7)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Nitin Kaushal(7)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Roy F. Waldron(8)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: Roy F. Waldron(8)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: James C. Oliver(11)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: James C. Oliver(11)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: All current Executive Officers and Directors as a group (7 persons)
Exact source ownership column: Percentage of Shares Beneficially Owned; After Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; After Offering; source holder: All current Executive Officers and Directors as a group (7 persons)
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding shares of common stock; not an additive ownership partition
On October 1, 2018, the Company entered into a Consulting Agreement with Kiriakos Capital for Kiriakos Capital Ltd. to provide investor relations and financing consulting services. Kiriakos Perperidis is an owner and officer of Kiriakos Capital Ltd. and beneficially owns more than 5% of our outstanding shares of common stock. The Consulting Agreement provides for a cash consulting fee of $6,000 per month, $96,000 of which has been deferred and remains due and owing as set forth in Deferred Consulting and Service Fees below.
Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: The following summary gives effect to the Reorganization in November 2025 and our December 9, 2025 1-for-3 reverse stock split.; complete original context retained; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained
Holders of our common stock are entitled to one vote for each share for the election of directors and on all other matters submitted to a vote of stockholders, and do not have cumulative voting rights in the election of directors. Whenever corporate action is to be taken by vote of the stockholders, it becomes authorized upon receiving the affirmative vote of a majority of the votes cast by all stockholders entitled to vote on the matter. Subject to preferences that may be granted to any holders of another class of shares, holders of our common stock are entitled to receive ratably only those dividends as may be declared by our board of directors out of funds legally available therefor, as well as any distributions to our stockholders. In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all of our assets remaining after we pay our liabilities and distribute the liquidation preference of any class of our shares that has a liquidation preference over our common stock. Source context: The following summary describes our capital stock and the material provisions of our certificate of incorporation, our bylaws and of the Delaware General Corporation Law. The following summary gives effect to the Reorganization in November 2025 and our December 9, 2025 1-for-3 reverse stock split. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our certificate of incorporation, bylaws and investors’ rights agreements, copies of which will be filed as exhibits to the registration statement of which this prospectus is part. Source context: Upon the closing of this offering, our authorized capital stock, will consist of 200,000,000 shares of our common stock, par value $0.001 per share, 45,000,000 shares of special voting stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. Prior to the completion of this offering, we expect to have approximately 400 holders of record of our common stock. The following description summarizes the terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description you should refer to our form of certificate of incorporation and our form of bylaws, as in effect immediately following the closing of this offering, copies of which will be filed as exhibits to the registration statement of which this prospectus is a part.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| Our directors, executive officers and holders of more than 5.0% of our outstanding shares of common stock or securities convertible into or exchangeable for shares of our common stockAfter date of this prospectus · Source conditions apply | 180 days |
| our directors, officers and holders of more than 5.0% of our outstanding common stockAfter date of this prospectus · Source conditions apply | 180 days |
| We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stockAfter date of this prospectus · Source conditions apply | 180 days |
| We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stockAfter date of this prospectus · Source conditions apply | 180 days |
Source and calculation
Our directors, executive officers and holders of more than 5.0% of our outstanding shares of common stock or securities convertible into or exchangeable for shares of our common stock have entered into lock-up agreements with the Representative pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of the Representative. Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the lock-up agreements expire, up to an additional approximately 18.2 million shares of common stock will be eligible for sale in the public market, which will be held by directors, executive officers and
SEC lock-up paragraph; source 832266:833599; SHA256 b5ffb148bd648975192ae1b07196530dbdf24c9a522a2c6eaf6b3176a0a8677d ↗We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
SEC table 7 row 8; source 261803:281649; SHA256 d138faa31ac38db614a9eef45bf2fe259407c16187ef87518137e3f880a9d7a9 ↗We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
SEC lock-up paragraph; source 280765:281616; SHA256 bc00fc0e1a4bf08760f5b6e7a177eac41fa2f2b46bf85747bfc654653f2e309b ↗We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
SEC table 7 row 8; source 261803:281649; SHA256 d138faa31ac38db614a9eef45bf2fe259407c16187ef87518137e3f880a9d7a9 ↗Source statements
Express180-day FINRA5110lock-up applies to underwriters warrants and underlying securities only. Three years describes warrant expiry/registration rights, not this restriction or an issuer lock-up. Source conditions retained; no calendar release inferred.
| Measure | Reported value |
|---|---|
| Underwriters’ warrants and underlying securities — Restriction (days) | 180 days |
Source and calculation
We have agreed to issue to the underwriters (or their permitted designees) warrants to purchase up to a total of 287,500 shares of common stock (5.0% of the shares of common stock issued in this offering, including shares of common stock sold upon exercise of the over-allotment option, if any). The warrants will be non-exercisable for six (6) months after the commencement of sales of the common stock in this offering and will expire three (3) years after the commencement of sales, which is also the effective date of the registration statement of which this prospectus is a part, which period is in compliance with applicable FINRA rules. The warrants are exercisable at a per share price equal to 125% of the initial public offering price per share of common stock issued in this offering. The warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(l)(A) of FINRA. The underwriters (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period commencing 180 days from the commencement of sales of the common stock in this offering. The underwriters’ warrants will have one demand and unlimited piggyback registration rights at our expense for a period of three years from the commencement of sales of the offering in compliance with applicable FINRA rules (provided such registration rights will not apply to any universal shelf registration statement). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.
SEC lock-up paragraph; source 2968074:2970885; SHA256 e8d53454648f41aee0c03a4461628cdd4d33e270cd28a78e402a4daedf54ff90 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- Our directors, executive officers and holders of more than 5.0% of our outstanding shares of common stock or securities convertible into or exchangeable for shares of our common stockOur directors, executive officers and holders of more than 5.0% of our outstanding shares of common stock or securities convertible into or exchangeable for shares of our common stock have entered into lock-up agreements with the Representative pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of the Representative. Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the lock-up agreements expire, up to an additional approximately 18.2 million shares of common stock will be eligible for sale in the public market, which will be held by directors, executive officers and
- our directors, officers and holders of more than 5.0% of our outstanding common stockWe, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
- We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stockWe, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
- We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stockWe, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
| Holder / event | Term / date | Conditions |
|---|---|---|
| Our directors, executive officers and holders of more than 5.0% of our outstanding shares of common stock or securities convertible into or exchangeable for shares of our common stock | 180 days | Our directors, executive officers and holders of more than 5.0% of our outstanding shares of common stock or securities convertible into or exchangeable for shares of our common stock have entered into lock-up agreements with the Representative pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of the Representative. Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the lock-up agreements expire, up to an additional approximately 18.2 million shares of common stock will be eligible for sale in the public market, which will be held by directors, executive officers and |
| our directors, officers and holders of more than 5.0% of our outstanding common stock | 180 days | We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information. |
| We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock | 180 days | We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information. |
| We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock | 180 days | We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information. |
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| Underwriters’ warrants and underlying securities — Restriction (days) | 180 days | We have agreed to issue to the underwriters (or their permitted designees) warrants to purchase up to a total of 287,500 shares of common stock (5.0% of the shares of common stock issued in this offering, including shares of common stock sold upon exercise of the over-allotment option, if any). The warrants will be non-exercisable for six (6) months after the commencement of sales of the common stock in this offering and will expire three (3) years after the commencement of sales, which is also the effective date of the registration statement of which this prospectus is a part, which period is in compliance with applicable FINRA rules. The warrants are exercisable at a per share price equal to 125% of the initial public offering price per share of common stock issued in this offering. The warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(l)(A) of FINRA. The underwriters (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period commencing 180 days from the commencement of sales of the common stock in this offering. The underwriters’ warrants will have one demand and unlimited piggyback registration rights at our expense for a period of three years from the commencement of sales of the offering in compliance with applicable FINRA rules (provided such registration rights will not apply to any universal shelf registration statement). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price. |
Basis and evidence
Our directors, executive officers and holders of more than 5.0% of our outstanding shares of common stock or securities convertible into or exchangeable for shares of our common stock have entered into lock-up agreements with the Representative pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of the Representative. Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the lock-up agreements expire, up to an additional approximately 18.2 million shares of common stock will be eligible for sale in the public market, which will be held by directors, executive officers and
SEC lock-up paragraph; source 832266:833599; SHA256 b5ffb148bd648975192ae1b07196530dbdf24c9a522a2c6eaf6b3176a0a8677d ↗We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
SEC table 7 row 8; source 261803:281649; SHA256 d138faa31ac38db614a9eef45bf2fe259407c16187ef87518137e3f880a9d7a9 ↗We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
SEC lock-up paragraph; source 280765:281616; SHA256 bc00fc0e1a4bf08760f5b6e7a177eac41fa2f2b46bf85747bfc654653f2e309b ↗We, our successors, all of our directors, officers and holders of more than 5.0% of our outstanding common stock have agreed with the Representative (as defined below), subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See “Underwriting” for more information.
SEC table 7 row 8; source 261803:281649; SHA256 d138faa31ac38db614a9eef45bf2fe259407c16187ef87518137e3f880a9d7a9 ↗We have agreed to issue to the underwriters (or their permitted designees) warrants to purchase up to a total of 287,500 shares of common stock (5.0% of the shares of common stock issued in this offering, including shares of common stock sold upon exercise of the over-allotment option, if any). The warrants will be non-exercisable for six (6) months after the commencement of sales of the common stock in this offering and will expire three (3) years after the commencement of sales, which is also the effective date of the registration statement of which this prospectus is a part, which period is in compliance with applicable FINRA rules. The warrants are exercisable at a per share price equal to 125% of the initial public offering price per share of common stock issued in this offering. The warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(l)(A) of FINRA. The underwriters (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period commencing 180 days from the commencement of sales of the common stock in this offering. The underwriters’ warrants will have one demand and unlimited piggyback registration rights at our expense for a period of three years from the commencement of sales of the offering in compliance with applicable FINRA rules (provided such registration rights will not apply to any universal shelf registration statement). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.
SEC lock-up paragraph; source 2968074:2970885; SHA256 e8d53454648f41aee0c03a4461628cdd4d33e270cd28a78e402a4daedf54ff90 ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reported · ConsolidatedOperating cash flow
$ · Annual values as reported · Consolidated| Calculation | FY2025 | FY2026 |
|---|---|---|
| Net income / (loss)Consolidated | ($9,477,969) | ($15,396,839) |
| Operating cash flowConsolidated | ($8,253,796) | ($8,576,956) |
| Calculation | Reported value |
|---|---|
| Current assets2026-03-31 · Consolidated | $1,802,461 |
| Current assets2025-03-31 · Consolidated | $1,457,929 |
| Total assets2026-03-31 · Consolidated | $7,675,191 |
| Total assets2025-03-31 · Consolidated | $7,045,775 |
| Current liabilities2026-03-31 · Consolidated | $8,178,223 |
| Current liabilities2025-03-31 · Consolidated | $7,326,226 |
| Total liabilities2026-03-31 · Consolidated | $10,736,107 |
| Total liabilities2025-03-31 · Consolidated | $8,506,121 |
| Total equity / (deficit)2026-03-31 · Consolidated | ($3,060,916) |
| Total equity / (deficit)2025-03-31 · Consolidated | ($1,460,346) |
| General and administrative expensesFY2026 · Consolidated | $7,724,398 |
| General and administrative expensesFY2025 · Consolidated | $6,683,621 |
Basis and evidence
Financial quality and runway
Financial quality and runway
For the year ended March 31, 2026, operating expenses were $15.29 million, operating loss was $15.29 million and net loss was $15.40 million, compared with a $9.48 million net loss in 2025. The filing includes going-concern and internal-control warnings.
EvidenceFinancial review 1Net loss increased from $9.48 million to $15.40 million year over year.
+
Net loss increased from $9.48 million to $15.40 million year over year.
EvidenceFinancial review 2The auditor’s report includes substantial doubt about going concern, and management identified a material weakness related to accounting resources.
+
The auditor’s report includes substantial doubt about going concern, and management identified a material weakness related to accounting resources.
MATERIAL CHANGES
The latest material signals and their investor impact are shown below.
Why it mattersCurrent filing reports 32,723,596 shares before the offering and 37,723,596 after it, versus 32,703,469 and 37,703,469 previously.
Evidence · THE OFFERINGWhy it mattersCurrent beneficial ownership figures and underwriter-warrant terminology/amounts differ from the previous excerpt; the current filing states up to 287,500 underwriter-warrant shares and approximately 45% lock-up coverage.
Evidence · Underwriters’ Warrants; Lock-Up AgreementsS-1/A0001213900-26-077653 ↗
Loading filing history…
The company is clinical-stage, has no approved commercial products and has incurred net losses since inception.
- Evidence
- Summary Risk Factors ↗
The company states that substantial additional capital will be needed even if the offering succeeds.
- Evidence
- Risk Factors ↗